
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Bcl-xS/L CRISPR/Cas9 KO Plasmid (m) | sc-419309 | 20 µg | $397.00 | |||
Bcl-xS/L HDR Plasmid (m) | sc-419309-HDR | 20 µg | $445.00 |
Mouse Bcl2l1 encodes the Bcl-x splice variants Bcl-xS and Bcl-xL, key regulators of mitochondrial outer membrane permeabilization that tune intrinsic apoptosis by controlling cytochrome c release and caspase activation. Bcl-xL is broadly pro-survival through sequestration of BH3-only proteins and inhibition of BAX/BAK oligomerization, whereas Bcl-xS can promote apoptosis, making the locus a central node in cellular stress responses. Bcl2l1 signaling interfaces with DNA damage pathways, growth factor–dependent survival programs, and metabolic control, influencing cell fate decisions in development and tissue homeostasis. Dysregulated Bcl2l1/Bcl-x activity is frequently studied in cancer biology, immune cell persistence, and neurodegeneration models where altered apoptotic thresholds contribute to disease-associated phenotypes.
Bcl-xS/L CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Bcl2l1 gene in mouse cell lines. Each plasmid in the pool co-expresses a unique sgRNA, targeting a distinct site within the Bcl2l1 locus, alongside the Streptococcus pyogenes Cas9 nuclease, and encodes GFP to enable fluorescent identification and enrichment of successfully transfected cells. This multi-guide strategy increases the likelihood of inducing frameshifts or deletions that produce a functional knockout, offering a more robust alternative to single-guide approaches. DSBs induced at multiple sites are resolved through non-homologous end joining (NHEJ) or, when used with the included HDR donor template, homology-directed repair (HDR) at a defined target site within the locus.
When used in conjunction with the RFP-expressing HDR donor, GFP and RFP fluorescence can be used together to distinguish transfected from edited cell populations, streamlining flow cytometry-based sorting and clone selection workflows.
For applications requiring confirmed, selectable knockout clones, Bcl-xS/L HDR Plasmid (m) includes an HDR donor construct containing a puromycin resistance cassette (PuroR) and a red fluorescent protein (RFP) reporter, flanked by homology arms specific to a defined Bcl2l1 target site.
When co-transfected with Bcl-xS/L CRISPR/Cas9 KO Plasmid (m):
The HDR donor construct features loxP sites flanking the PuroR-RFP selection cassette to allow clean marker removal following clone confirmation. Transient expression of Cre recombinase via the included Cre Vector: sc-418923 excises the cassette, leaving a minimal residual loxP site within the Bcl2l1 locus and eliminating potential confounding effects on downstream assays.
This two-step approach:
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.